Search results
Nucleus RadioPharma secures Series A investment from AstraZeneca
BioPharma-Reporter· 1 day agoThe investment from AstraZeneca marks a strategic move to further expand Nucleus's capabilities in developing targeted radiotherapies and theranostics, aimed at making cancer ...
AstraZeneca invests in Nucleus RadioPharmaceuticals - Minneapolis / St. Paul Business Journal
The Business Journals· 1 day agoAfter completing a $56 million Series A funding round in 2023, Nucleus RadioPharma scored an...
AstraZeneca completes acquisition of biopharma company Fusion Pharma
dpa international via Yahoo Finance· 2 days agoBritish pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition...
First Trust Advisors LP Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 1 day agoFirst Trust Advisors LP grew its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% in the fourth quarter, according to its most recent filing with the Securities ...
BMO maintains target on AstraZeneca shares, cites trial success By Investing.com
Investing.com· 2 days agoOn Wednesday, BMO Capital upheld its Outperform rating on AstraZeneca (NASDAQ:AZN) with a steady...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 15 hours agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks via Yahoo Finance· 4 days agoAstrazeneca (AZN) closed the most recent trading day at $78.99, moving +1.24% from the previous...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 3 days agoThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
AstraZeneca finalizes Fusion Pharmaceuticals buyout By Investing.com
Investing.com· 3 days agoThis move is aligned with AstraZeneca (NASDAQ:AZN)'s strategy to advance cancer therapy by focusing...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 5 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...